Abstract |
The prognosis of adult patients with relapsed acute lymphoblastic leukemia (ALL) remains poor. Recent studies in adolescents and young adults reported better outcomes when therapy was intensified. Based on hyper-CVAD ( cyclophosphamide/ vincristine/ doxorubicin/ dexamethasone) as a backbone, we designed an augmented version with intensified doses of vincristine, dexamethasone, and asparaginase (L- asparaginase in the first 62 patients and pegaspargase in the remainder) starting from course 1. Ninety patients have been enrolled, with a median age of 34 years (range, 14-70 years). Most patients (78%) had pre-B ALL and were in first salvage (76%), with a first remission duration of 12.6 months (range, 1-78 months). Ten patients had primary refractory disease. Of 88 evaluable patients, 41 (47%) achieved complete remission (CR), with a median time to CR of 29 days (range, 18-80 days). Eight patients (9%) died within the first 30 days. Median CR duration, progression-free survival, and overall survival were 5, 6.2, and 6 months, respectively. Median overall survival of CR patients was 10.2 months (range, 1.4-69.5+ months). Twenty-eight patients (32%) proceeded to stem cell transplantation. Myelosuppression-associated complications were frequent. Pegaspargase was equally effective and easier to administer than L- asparaginase. Augmented hyper-CVAD may be suitable to be studied in younger adults with untreated ALL.
|
Authors | Stefan Faderl, Deborah Ann Thomas, Susan O'Brien, Farhad Ravandi, Guillermo Garcia-Manero, Gautam Borthakur, Alessandra Ferrajoli, Srdan Verstovsek, Mohamed Ayoubi, Michael Rytting, Jennie Feliu, Hagop M Kantarjian |
Journal | Clinical lymphoma, myeloma & leukemia
(Clin Lymphoma Myeloma Leuk)
Vol. 11
Issue 1
Pg. 54-9
(Feb 2011)
ISSN: 2152-2669 [Electronic] United States |
PMID | 21454191
(Publication Type: Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Vincristine
- Dexamethasone
- Asparaginase
|
Topics |
- Adolescent
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols
(administration & dosage, adverse effects)
- Asparaginase
(administration & dosage, adverse effects)
- Dexamethasone
(administration & dosage, adverse effects)
- Disease-Free Survival
- Drug Administration Schedule
- Female
- Humans
- Male
- Middle Aged
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
(drug therapy)
- Prognosis
- Salvage Therapy
- Survival Analysis
- Vincristine
(administration & dosage, adverse effects)
- Young Adult
|